Biogen
Royalty Pharma Invests $250M in Biogen’s Late-Stage Lupus Treatment
Biogen, Royalty Pharma, litifilimab, lupus, Phase 3 trials, R&D funding, systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE)
FDA Approves Monthly Maintenance Dosing for Eisai and Biogen’s Alzheimer’s Drug Leqembi
Leqembi, Alzheimer’s disease, FDA approval, monthly maintenance dosing, Eisai, Biogen, amyloid-beta, cognitive decline
Sage Therapeutics Rejects Biogen’s Acquisition Bid, Initiates Strategic Review
Sage Therapeutics, Biogen, acquisition rejection, strategic alternatives, ZURZUVAE, postpartum depression, pharmaceutical industry, M&A
Sage Therapeutics Rejects Biogen’s Acquisition Proposal, Remains Open to Future Deals
Sage Therapeutics, Biogen, Acquisition Proposal, Postpartum Depression, ZURZUVAE, Neurodevelopmental Disorders, Neuropsychiatry
Biogen’s Strategic Pivot: Emphasizing External Collaborations and Diversification
Biogen, research strategy, external collaborations, diversification, Alzheimer’s disease, rare diseases, immunology, neuroscience, neurodegeneration
Sage Therapeutics Files Lawsuit Against Biogen Following $469 Million Acquisition Offer
Sage Therapeutics, Biogen, lawsuit, acquisition offer, $469 million, neuroscience, pharmaceutical industry
Alzheimer’s Market Set for Eightfold Boom: Lilly, Eisai, and Biogen Lead the Charge
Alzheimer’s disease market, Eli Lilly, Eisai, Biogen, Market growth, Donanemab (Kisunla), Leqembi
Biogen Proposes Acquisition of Sage Therapeutics in $442 Million Deal
Biogen, Sage Therapeutics, acquisition, neuro biotech, zuranolone, postpartum depression, major depressive disorder
Eisai Slashes Leqembi Sales Forecast Amid Continued Launch Challenges
Eisai, Leqembi, Alzheimer’s disease, sales forecast, revenue expectations, Biogen, pharmaceutical industry
Biogen Raises Profit Guidance Amid Leqembi Growth and MS Sales Decline
Biogen, profit guidance, Leqembi, multiple sclerosis, earnings report, pharmaceutical industry